A recording will be available until 10th February 2020. Please see playback details below:
UK 020 3936 3001
USA 1 845 709 8569
All other locations: +44 20 3936 3001
Access code: 732473
-- ENDS --
Hikma Pharmaceuticals PLC
Susan Ringdal EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
Deputy Director of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
Senior Investor Relations Manager
+44 (0)20 3892 4389/ +44 7973 679502
Ben Atwell/Andrew Ward
+44 (0)20 3727 1000
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...